{"id":22489,"date":"2017-11-11T07:53:36","date_gmt":"2017-11-11T02:23:36","guid":{"rendered":"https:\/\/cardiophile.org\/?p=22489"},"modified":"2022-11-30T04:56:25","modified_gmt":"2022-11-29T23:26:25","slug":"cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/","title":{"rendered":"Cangrelor &#8211; short acting P2Y12 inhibitor for intravenous use"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/YbcsYvyyyaU\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h2><span style=\"color: #008000;\">Cangrelor<\/span><\/h2>\n<p>Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons. Plasma half life of the drug is 3 to 6 minutes only and the offset of its therapeutic action occurs in about one hour. If we are planning to use the drug in the cath lab, loading dose of oral P2Y12 inhibitor in the emergency department can be withheld.<\/p>\n<p>The drug can be considered as Class IIb, level of evidence A indication for those undergoing percutaneous coronary intervention when they have not been treated with P2Y12 inhibitors earlier [1]. This is because of early onset of antiplatelet action. In case urgent surgery is needed, early offset of action is an added advantage.<\/p>\n<p>In fact, cangrelor has been considered as a bridge therapy while withholding oral P2Y12 inhibitors prior to elective surgery in those with high risk of coronary thrombosis as in those with a recently implanted drug eluting coronary stent. This bridging is considered in the 5-7 days during which an antiplatelet agent is withheld prior to surgery.<\/p>\n<p>BRIDGE trial evaluated patients taken for coronary artery bypass grafting. In that study, cangrelor was discontinued 1-6 hours prior to surgery, while aspirin was continued throughout the perioperative period. Bridging with cangrelor did not increase major bleeds prior to surgery, though minor bleeds, mostly ecchymosis at venipuncture site, was higher. P2Y<sub>12<\/sub> assay documented sufficient platelet inhibition corresponding to levels required for anti thrombotic effect [2].<\/p>\n<p>CHAMPION PHOENIX was a double blind placebo controlled trial which randomized 11,145 patients undergoing urgent or elective PCI and were receiving guideline recommended therapy. They would receive either a bolus and infusion of cangrelor or a loading dose of 600 mg or 300 mg clopidogrel. Cangrelor significantly reduced ischemic events including stent thrombosis during PCI with no significant increase in severe bleeding [3].<\/p>\n<p>SWAP-5 Study was a randomized double blind placebo controlled crossover trial. It was a pharmacokinetic and pharmacodynamic study in 20 patients with coronary artery disease pre-treated with a 180 mg loading dose of ticagrelor and randomized to either placebo or cangrelor bolus and infusion for 2 hours. Crossover was after 1-4 weeks of wash out. Compared with placebo, use of cangrelor in patients pre-treated with ticagrelor resulted in enhanced platelet inhibition. There were no differences in pharmacokinetic and pharmacodynamic profiles after discontinuation of drug infusion, indicating the absence of a drug-drug interaction [4].<\/p>\n<p><span style=\"color: #0000ff;\"><strong>References<\/strong><\/span><\/p>\n<ol>\n<li>De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34212768\/\">Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives<\/a>. J Am Heart Assoc. 2021 Jul 6;10(13):e022125. doi: 10.1161\/JAHA.121.022125. Epub 2021 Jul 2. PMID: 34212768; PMCID: PMC8403274.<\/li>\n<li>Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307:265\u2013274.<\/li>\n<li>Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsk\u00fd P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, G\u00e9n\u00e9reux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23473369\/\">Effect of platelet inhibition with cangrelor during PCI on ischemic events<\/a>. N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056\/NEJMoa1300815. Epub 2013 Mar 10. PMID: 23473369.<\/li>\n<li>Franchi F, Ortega-Paz L, Rollini F, Galli M, Been L, Ghanem G, Shalhoub A, Ossi T, Rivas A, Zhou X, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Angiolillo DJ. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36317958\/\">Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study<\/a>. JACC Cardiovasc Interv. 2022 Oct 21:S1936-8798(22)02005-2. doi: 10.1016\/j.jcin.2022.10.034. Epub ahead of print. PMID: 36317958.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.<\/p>\n","protected":false},"author":1,"featured_media":22491,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-22489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cangrelor - short acting P2Y12 inhibitor for intravenous use<\/title>\n<meta name=\"description\" content=\"Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cangrelor - short acting P2Y12 inhibitor for intravenous use\" \/>\n<meta property=\"og:description\" content=\"Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-11T02:23:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-29T23:26:25+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Cangrelor &#8211; short acting P2Y12 inhibitor for intravenous use\",\"datePublished\":\"2017-11-11T02:23:36+00:00\",\"dateModified\":\"2022-11-29T23:26:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/\"},\"wordCount\":635,\"commentCount\":4,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/\",\"name\":\"Cangrelor - short acting P2Y12 inhibitor for intravenous use\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2017-11-11T02:23:36+00:00\",\"dateModified\":\"2022-11-29T23:26:25+00:00\",\"description\":\"Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cangrelor &#8211; short acting P2Y12 inhibitor for intravenous use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cangrelor - short acting P2Y12 inhibitor for intravenous use","description":"Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/","og_locale":"en_US","og_type":"article","og_title":"Cangrelor - short acting P2Y12 inhibitor for intravenous use","og_description":"Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.","og_url":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2017-11-11T02:23:36+00:00","article_modified_time":"2022-11-29T23:26:25+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Cangrelor &#8211; short acting P2Y12 inhibitor for intravenous use","datePublished":"2017-11-11T02:23:36+00:00","dateModified":"2022-11-29T23:26:25+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/"},"wordCount":635,"commentCount":4,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/","url":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/","name":"Cangrelor - short acting P2Y12 inhibitor for intravenous use","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#primaryimage"},"thumbnailUrl":"","datePublished":"2017-11-11T02:23:36+00:00","dateModified":"2022-11-29T23:26:25+00:00","description":"Cangrelor is a short acting P2Y12 inhibitor for intravenous use. It is a directly acting non thienopyridine P2Y12 receptor antagonist analogous to adenosine triphosphate molecule, having a molecular weight of 88 Daltons.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/cangrelor-short-acting-p2y12-inhibitor-for-intravenous-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Cangrelor &#8211; short acting P2Y12 inhibitor for intravenous use"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/22489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=22489"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/22489\/revisions"}],"predecessor-version":[{"id":57087,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/22489\/revisions\/57087"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=22489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=22489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=22489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}